Kamada Ltd ( (KMDA) ) has released its Q1 earnings. Here is a breakdown of the information Kamada Ltd presented to its investors.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Kamada Ltd. is a global biopharmaceutical company specializing in specialty plasma-derived therapies for rare and serious conditions, with a focus on organic growth, business development, and innovative clinical trials.
Kamada Ltd. reported a strong financial performance for the first quarter of 2025, highlighted by a 17% increase in revenues and a 54% rise in adjusted EBITDA compared to the previous year. The company continues to demonstrate robust growth through its diverse product portfolio and strategic management.
Key financial metrics for the quarter include total revenues of $44.0 million and an adjusted EBITDA of $11.6 million. Kamada also expanded its plasma collection operations with a new site in San Antonio, Texas, and launched a post-marketing research program for CYTOGAM®. The company maintains a strong financial position to pursue mergers, acquisitions, and in-licensing opportunities.
Looking ahead, Kamada reiterates its full-year guidance for 2025, expecting double-digit profitable growth. The company remains committed to its strategic growth pillars, including advancing its Phase 3 Inhaled AAT program and expanding its commercial operations.